146 related articles for article (PubMed ID: 29939279)
1. IL-1 Antagonism in Men With Metabolic Syndrome and Low Testosterone: A Randomized Clinical Trial.
Ebrahimi F; Urwyler SA; Straumann S; Doerpfeld S; Bernasconi L; Neyer P; Schuetz P; Mueller B; Donath MY; Christ-Crain M
J Clin Endocrinol Metab; 2018 Sep; 103(9):3466-3476. PubMed ID: 29939279
[TBL] [Abstract][Full Text] [Related]
2. Symptomatic response to testosterone treatment in dieting obese men with low testosterone levels in a randomized, placebo-controlled clinical trial.
Ng Tang Fui M; Hoermann R; Prendergast LA; Zajac JD; Grossmann M
Int J Obes (Lond); 2017 Mar; 41(3):420-426. PubMed ID: 28028318
[TBL] [Abstract][Full Text] [Related]
3. The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study).
Hackett G; Cole N; Bhartia M; Kennedy D; Raju J; Wilkinson P; Saghir A;
Int J Clin Pract; 2014 Feb; 68(2):203-15. PubMed ID: 24355040
[TBL] [Abstract][Full Text] [Related]
4. Testosterone undecanoate improves sexual function in men with type 2 diabetes and severe hypogonadism: results from a 30-week randomized placebo-controlled study.
Hackett G; Cole N; Saghir A; Jones P; Strange RC; Ramachandran S
BJU Int; 2016 Nov; 118(5):804-813. PubMed ID: 27124889
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-18 and testosterone levels in men with metabolic syndrome.
Angelova P; Kamenov Z; Tsakova A; El-Darawish Y; Okamura H
Aging Male; 2018 Jun; 21(2):130-137. PubMed ID: 29168426
[TBL] [Abstract][Full Text] [Related]
6. Effects of testosterone supplementation on depressive symptoms and sexual dysfunction in hypogonadal men with the metabolic syndrome.
Giltay EJ; Tishova YA; Mskhalaya GJ; Gooren LJ; Saad F; Kalinchenko SY
J Sex Med; 2010 Jul; 7(7):2572-82. PubMed ID: 20524974
[TBL] [Abstract][Full Text] [Related]
7. Interleukin-1 Antagonism Decreases Cortisol Levels in Obese Individuals.
Urwyler SA; Schuetz P; Ebrahimi F; Donath MY; Christ-Crain M
J Clin Endocrinol Metab; 2017 May; 102(5):1712-1718. PubMed ID: 28324042
[TBL] [Abstract][Full Text] [Related]
8. Effects of aromatase inhibition in hypogonadal older men: a randomized, double-blind, placebo-controlled trial.
Burnett-Bowie SA; Roupenian KC; Dere ME; Lee H; Leder BZ
Clin Endocrinol (Oxf); 2009 Jan; 70(1):116-23. PubMed ID: 18616708
[TBL] [Abstract][Full Text] [Related]
9. Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial.
Marks LS; Mazer NA; Mostaghel E; Hess DL; Dorey FJ; Epstein JI; Veltri RW; Makarov DV; Partin AW; Bostwick DG; Macairan ML; Nelson PS
JAMA; 2006 Nov; 296(19):2351-61. PubMed ID: 17105798
[TBL] [Abstract][Full Text] [Related]
10. A randomized, double-blind, placebo-controlled trial on the effect of long-acting testosterone treatment as assessed by the Aging Male Symptoms scale.
Ho CC; Tong SF; Low WY; Ng CJ; Khoo EM; Lee VK; Zainuddin ZM; Tan HM
BJU Int; 2012 Jul; 110(2):260-5. PubMed ID: 22093057
[TBL] [Abstract][Full Text] [Related]
11. Effects of interleukin-1 antagonism and corticosteroids on fibroblast growth factor-21 in patients with metabolic syndrome.
Ebrahimi F; Urwyler SA; Betz MJ; Christ ER; Schuetz P; Mueller B; Donath MY; Christ-Crain M
Sci Rep; 2021 Apr; 11(1):7911. PubMed ID: 33846498
[TBL] [Abstract][Full Text] [Related]
12. Effects of Testosterone Administration for 3 Years on Subclinical Atherosclerosis Progression in Older Men With Low or Low-Normal Testosterone Levels: A Randomized Clinical Trial.
Basaria S; Harman SM; Travison TG; Hodis H; Tsitouras P; Budoff M; Pencina KM; Vita J; Dzekov C; Mazer NA; Coviello AD; Knapp PE; Hally K; Pinjic E; Yan M; Storer TW; Bhasin S
JAMA; 2015 Aug; 314(6):570-81. PubMed ID: 26262795
[TBL] [Abstract][Full Text] [Related]
13. Vitamin D and Testosterone in Healthy Men: A Randomized Controlled Trial.
Lerchbaum E; Pilz S; Trummer C; Schwetz V; Pachernegg O; Heijboer AC; Obermayer-Pietsch B
J Clin Endocrinol Metab; 2017 Nov; 102(11):4292-4302. PubMed ID: 28938446
[TBL] [Abstract][Full Text] [Related]
14. Oral enclomiphene citrate raises testosterone and preserves sperm counts in obese hypogonadal men, unlike topical testosterone: restoration instead of replacement.
Kim ED; McCullough A; Kaminetsky J
BJU Int; 2016 Apr; 117(4):677-85. PubMed ID: 26496621
[TBL] [Abstract][Full Text] [Related]
15. Effects of interleukin-1 antagonism on cortisol levels in individuals with obesity: a randomized clinical trial.
Ebrahimi F; Urwyler SA; Schuetz P; Mueller B; Bernasconi L; Neyer P; Donath MY; Christ-Crain M
Endocr Connect; 2019 Jun; 8(6):701-708. PubMed ID: 31042669
[TBL] [Abstract][Full Text] [Related]
16. Low-grade inflammation in survivors of childhood cancer and testicular cancer and its association with hypogonadism and metabolic risk factors.
Ekedahl H; Isaksson S; Ståhl O; Bogefors K; Romerius P; Eberhard J; Giwercman A
BMC Cancer; 2022 Feb; 22(1):157. PubMed ID: 35135482
[TBL] [Abstract][Full Text] [Related]
17. Marked testosterone deficiency-related symptoms may be associated to higher metabolic risk in men with low testosterone levels.
García-Cruz E; Leibar-Tamayo A; Romero-Otero J; Asiaín I; Carrión A; Castañeda R; Mateu L; Luque P; Cardeñosa O; Alcaraz A
J Sex Med; 2014 Sep; 11(9):2292-301. PubMed ID: 24975551
[TBL] [Abstract][Full Text] [Related]
18. MANAGEMENT OF ENDOCRINE DISEASE: Rationale and current evidence for testosterone therapy in the management of obesity and its complications.
Lapauw B; Kaufman JM
Eur J Endocrinol; 2020 Dec; 183(6):R167-R183. PubMed ID: 33105105
[TBL] [Abstract][Full Text] [Related]
19. Effects of testosterone undecanoate on cardiovascular risk factors and atherosclerosis in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 24-month, randomized, double-blind, placebo-controlled study.
Aversa A; Bruzziches R; Francomano D; Rosano G; Isidori AM; Lenzi A; Spera G
J Sex Med; 2010 Oct; 7(10):3495-503. PubMed ID: 20646185
[TBL] [Abstract][Full Text] [Related]
20. Effects of long-term testosterone administration on cognition in older men with low or low-to-normal testosterone concentrations: a prespecified secondary analysis of data from the randomised, double-blind, placebo-controlled TEAAM trial.
Huang G; Wharton W; Bhasin S; Harman SM; Pencina KM; Tsitouras P; Li Z; Hally KA; Asthana S; Storer TW; Basaria S
Lancet Diabetes Endocrinol; 2016 Aug; 4(8):657-665. PubMed ID: 27377542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
